What does AIRNA do?
AIRNA is a biotechnology firm that specializes in RNA editing therapeutics. By leveraging its proprietary platform, the company studies natural mechanisms to precisely edit target RNA, aiming to repair disease-causing mutations and introduce beneficial genetic variants for improved patient outcomes.
How much did they raise?
The company raised $155M in Series B funding, with the round led by Venrock Healthcare Capital Partners and Forbion Growth, and supported by participants including RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, and ND Capital. This significant capital injection underscores strong investor confidence as AIRNA positions itself for critical clinical advancements.
What are their plans for the money?
With the fresh infusion of funds, AIRNA plans to advance its lead RNA editing candidate, AIR-001, into Phase 1/2 clinical trials for AATD, while also expanding its pipeline of novel RNA-editing medicines for cardiometabolic and other diseases. The investment is expected to accelerate clinical development, potentially transforming treatment paradigms and offering new hope for patients.
What have they achieved so far?
AIRNA has already made impressive strides in its field, evidenced by its robust proprietary platform and its research operations established in Tübingen, Germany. The company's progress in uncovering the mechanisms of RNA editing positions it well to achieve its ambitious therapeutic goals.
